{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-016725","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.648168+00:00","generated_at":"2026-05-26T04:49:59.722821+00:00","sec_items":["1.02","2.02","2.05","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart","bullets":["ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).","2025 ARCALYST revenue guidance $560-580M; expects annual cash flow positive.","Terminated MedImmune license for mavrilimumab; effective May 22, 2025.","Discontinued abiprubart Phase 2b trial in Sjögren's Disease; expects $14-17M additional expenses.","Net loss Q4 $8.9M (vs net income $25.2M); full year net loss $43.2M (vs net income $14.1M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-016725","json":"https://secwatch.observer/filing/0001104659-25-016725.json","markdown":"https://secwatch.observer/filing/0001104659-25-016725.md","text":"https://secwatch.observer/filing/0001104659-25-016725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/0001104659-25-016725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/tm257489d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:49:59.722821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}